Smart Biofactory Insilico, MCT to Provide Digital Twin-based Solution for Biologics Production

Editor: Ahlam Rais

Insilico Biotechnology and Meyer Chroma Technology (MCT) have partnered together to deliver an integrated digital twin-based solution for biologics manufacturing and purification. The software platform will include modeling tools for the upstream as well as downstream processes.

Related Vendors

Bioproduction facility: The one-stop-shop solution will enable customers to build smarter biofactories for biologics production in the future.
Bioproduction facility: The one-stop-shop solution will enable customers to build smarter biofactories for biologics production in the future.
(Source: Insilico Biotechnology)

Stuttgart/Germany – Insilico Biotechnology and Meyer Chroma Technology (MCT) have recently announced that they will be joining forces to provide the biopharma industry with an eco-system of Digital Twins enabling integrated predictive process modeling for process development, manufacturing and product purification.

Insilico has been providing the biopharmaceutical industry with its unique Digital Twin based platform for the upstream process development and manufacturing since 2018. The Insilico Digital Twins allowed the biopharmaceutical companies to successfully simulate cell culture processes, resulting in robust process development and manufacturing.

Sharing the vision of the Smart Biofactory, MCT is now joining forces with Insilico to provide the industry with an integrated Digital Twin based solution for biologics manufacturing and purification. Since its start MCT is providing its customers with its purification Digital Twin-based tools.

China’s Pharmaceutical Equipment Market - Current Status, Trends and Recommendations for Action

As China is emerging as one of the world’s fastest-growing markets for the consumption of pharmaceuticals, it also offers huge opportunities for the global equipment industry.

This 40-page report aims to help you gain a better understanding of the current China's pharmaceutical market regarding a series of pharmaceutical industry related policies. Based on results of the survey among users in the pharmaceutical industry and the expert interviews, it will also provide you with a forecast for the industry and recommendations for your future operating and investment in China.

The combined software platform that includes modeling tools for both the upstream and the downstream processes is intended to meet the high demand of the biopharmaceutical companies for a full process modeling of all phases of manufacturing and purification allowing the optimization of the whole process from production in cell culture to subsequent purification. This will result in processes with superior productivity and best-in-class product quality and robustness.

Klaus Mauch, the CEO of Insilico, says: "We are excited to establish our collaboration with MCT, and pleased to offer our customers a comprehensive solution platform that combines MCT’s experience in the downstream process modeling with Insilico’s upstream modeling tools. This would be an unprecedented step forward towards the full digitization of the biofactory."

Kristian Meyer, CEO of MCT, explains: “This partnership creates new opportunities by linking the core strengths of Insilico and MCT to bring a novel one-stop-shop solution for predictive technologies into the marketplace. This will ultimately enable our customers to build smarter biofactories for biologics production in the future.”

(ID:47177976)